1. |
祝伟星, 王启俊, 李玲, 等. 北京城区1993-1997年恶性肿瘤发病率分析[J]. 肿瘤防治杂志, 2003, 10(8): 785-787.
|
2. |
上海市肿瘤研究所. 1998年上海市区恶性肿瘤发病率[J]. 肿瘤, 2001, 21(4): 312.
|
3. |
陈可欣, 王庆生, 王继芬, 等. 天津市常见肿瘤流行病学分析[J]. 中国肿瘤, 1999, 8(3): 118-119.
|
4. |
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med, 2002, 347(16): 1233-1241.
|
5. |
Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer[J]. N Engl J Med, 2002, 347(16): 1227-1232.
|
6. |
王永胜, 欧阳涛, 王启堂, 等. 中国前哨淋巴结活检多中心协作研CBCSG-001最新资料报告[J/CD]. 中华乳腺病杂志(电子版), 2009, 3(3): 8-12.
|
7. |
Pepels MJ, Vestjens JH, De BM, et al. Safety of avoiding routine use of axillary dissection in early stage breast cancer:a systematic review[J]. Breast Cancer Res Treat, 2011, 125(2): 301-313.
|
8. |
骆成玉. 乳腔镜在乳腺外科手术中的应用现状[J/CD]. 中华乳腺病杂志(电子版), 2008, 2(6): 620-625.
|
9. |
姜军, 杨新华, 范林军, 等. 腔镜手术在乳腺疾病外科治疗中的应用[J]. 中华医学杂志, 2005, 85(3): 181-183.
|
10. |
李宏江, 彭玉兰, 汪静, 等. 乳腺肿块微创切除和/或活检的新技术——Mammotome手术[J]. 中国普外基础与临床杂志, 2005, 12(3): 235-237.
|
11. |
龙泉伊, 张海燕, 秦平, 等. Mammotome微创旋切术治疗乳腺肿瘤680例分析[J]. 华西医学, 2009, 24(9): 2373-2375.
|
12. |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊断治疗指南与规范(2007版)[J]. 中国癌症杂志, 2007, 17(5): 410-428.
|
13. |
Spear SL, Mardini S, Ganz JC. Resource cost comparison of implant-based breast reconstruction versus tram flap breast reconstruction[J]. Plast Reconstr Surg, 2003, 112(1): 101-105.
|
14. |
Blondeel N, Vanderstraeten GG, Monstrey SJ, et al. The donor site morbidity of free DIEP flaps and free tram flaps for breast reconstruction[J]. Br J Plast Surg, 1997, 50(5): 322-330.
|
15. |
Early breast cancer Trialists’collaborative Group. Tamoxifen for early breast cancer:an overviewof the randomized trials[J]. Lancet, 1998, 351(9114): 1451-1467.
|
16. |
Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial[J]. Lancet Oncol, 2010, 11(12): 1135-1141.
|
17. |
Regan MM, Price KN, Giobbie-Hurder A, et al. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase Ⅲ trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer[J]. Breast Cancer Res, 2011, 13(3): 209.
|
18. |
Bartlett JM, Brookes CL, Robson T, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy:a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial[J]. J Clin Oncol, 2011, 29(12): 1531-1538.
|
19. |
Ingle J, Dowsett M, Cuzick J, et al. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor-positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies[J]. Cancer Res, 2009, 69(Suppl 2): 66.
|
20. |
Early breast cancer Trialists′collaborative Group. Polychemotherapy for early breast cancer:an overviewof the randomized trials[J]. Lancet, 1998, 352(9132): 930-932.
|
21. |
Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J]. J Clin Oncol, 2003, 21(6): 976-983.
|
22. |
李宏江, 敬静, 汪静, 等. 新辅助化疗对晚期乳腺癌的影响[J]. 中国肿瘤临床杂志, 2006, 33(3): 157-159.
|
23. |
张斌, 蔡玉娥, 张齐, 等. 新辅助化疗用于可手术乳腺癌的10年疗效[J]. 中国肿瘤临床, 2002, 29(3): 157-159, 163.
|
24. |
Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from nsabp B-28[J]. J Clin Oncol, 2005, 23(16): 3686-3696.
|
25. |
Martin M, Pienkowski T, Mackey J, et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up[J]. Breas Cancer Res Treat, 2003, 82(Suppl 1): 43.
|
26. |
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer[J]. N Engl J Med, 2005, 353(16): 1673-1684.
|
27. |
Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide(AC)→paclitaxel(T) vs. AC→T with trastuzumab(H) [J]. Proc Am Soc Clin Oncol, 2007, 25(18S): 964s.
|
28. |
Sawaki M, Tokudome N, Mizuno T, et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in her2-positive elderly breast cancer patients: randomized controlled trial [respect (N-SAS BC07)[J]. Jpn J Clin Oncol, 2011, 41(5): 709-712.
|
29. |
Andersson M, Lidbrink E, Bjerre K, et al. Phase Ⅲ randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer:the hernata study[J]. J Clin Oncol, 2011, 29(3): 264-271.
|
30. |
Robert NJ, Diéras V, Glaspy J, et al. Ribbon-1: randomized, double-blind, placebo-controlled, phase Ⅲ trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer[J]. J Clin Oncol, 2011, 29(10): 1252-1260.
|
31. |
Hurvitz SA, Allen HJ, Moroose RL, et al. A phase II trial of docetaxel with bevacizumab as first-line therapy for her2-negative metastatic breast cancer (TORI B01)[J]. Clin Breast Cancer, 2010, 10(4): 307-312.
|
32. |
Forero-torres A, Saleh MN, Galleshaw JA, et al. Pilot trial of preoperative(neoadjuvant)letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer[J]. Clin Breast Cancer, 2010, 10(4): 275-280.
|
33. |
Terpos E, Efstathiou E, Christoulas D, et al. Rankl inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases[J]. Expert Opin Biol Ther, 2009, 9(4): 465-479.
|
34. |
Stopeck A, Body JJ, Fujiwara Y, et al. 2LBA denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study[J]. Eur J Cancer Suppl, 2009, 7(3): 2-3.
|
35. |
Santini D, Galluzzo S, Zoccoli A, et al. New molecular targets in bone metastases[J]. Cancer Treat Rev, 2010, 36(Suppl 3): S6-S10.
|
36. |
Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients With breast cancer-related bone metastases[J]. J Clin Oncol, 2007, 25(28): 4431-4437.
|
37. |
田明嫄, 黄安斌. Denosumab在骨破坏性疾病中的应用进展[J]. 中华风湿病学杂志, 2009, 13(5): 349-352.
|
38. |
Henry DH, Costa L, Goldwasser F, et al. Randomized,double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer(excluding breast and prostate cancer)or multiple myeloma[J]. J Clin Oncol, 2011, 29(9): 1125-1132.
|
39. |
Ashok V, Dash C, Rohan TE, et al. Selective cyclooxygenase-2(cox-2)inhibitors and breast cancer risk[J]. Breast, 2011, 20(1): 66-70.
|
40. |
Falandry C, Debled M, Bachelot T, et al. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients:a double-blind phase Ⅲ gineco study[J]. Breast Cancer Res Treat, 2009, 116(3): 501-508.
|
41. |
Rudat V, Alaradi AA, Mohamed A, et al. Tangential beam IMRT versus tangential beam 3D-CRT of the chest wall in postmastectomy breast cancer patients: a dosimetric comparison[J]. Radiat Oncol, 2011, 6: 26.
|
42. |
Reshma J, Moran J, Marsh R, et al. Evaluation of four techniques using intensity-modulated radiation therapy for comprehensive locoregional irradiation of breast cancer[J]. Int J Radiat Oncol Biol Phys, 2010, 78(5): 1594-1603.
|